Financial Statements

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (APVO)

$7.6
-0.27 (-3.43%)

Income Statement

Quarter data

Balance Sheet Statement

Quarter data
Year 2019 2018 2017 2016
Short-term debt -3.330.8019.86
Other Assets -10.008.3515.05
Total current liabilities 19.5418.5117.6138.24
Cash and cash equivalents 9.687.0930.6412.45
Long-term debt 18.3815.7319.283.33
Cash and short-term investments 54.5280.7830.7424.94
Total debt 18.3819.0620.0723.19
Inventories 6.641.031.786.14
Deferred revenue 0.81---
Goodwill and Intangible Assets 14.536.085.254.42
Total non-current liabilities 22.3216.6919.483.33
Total non-current assets 20.4421.9218.8023.41
Total liabilities 41.2934.9737.0941.57
Total assets 91.86117.0167.4953.41
Other comprehensive income 131.27155.84157.79179.65
Short-term investments 44.8573.690.1012.49
Property, Plant & Equipment Net 5.915.845.203.95
Net Debt 8.7111.97-10.5610.74
Investments 44.8573.690.1012.49
Total shareholders equity 50.5782.0330.4111.84
Retained earnings (deficit) -80.69-73.72-127.41-167.86
Long-term investments ----
Receivables 4.282.145.227.02
Payables 11.497.3511.6713.04
Total current assets 71.4195.0848.6930.00

Cash Flow Statement

Quarter data
Year 2019 2018 2017 2016
Operating Cash Flow -36.86-41.57-51.42-42.38
Free Cash Flow -39.37-42.98-52.40-42.54
Capital Expenditure 2.511.400.980.15
Depreciation & Amortization 3.363.132.392.23
Acquisitions and disposals ----
Deferred income taxes -15.82-0.00--
Investment purchases -44.88-99.63-16.54-
Accounts payables 2.480.201.280.94
Sales/Maturities of investments ----
Change in working capital 84.20-56.55-2.26-5.77
Debt repayment 0.161.36--0.14
Other non-cash items ----
Investing Cash Flow -47.3929.4672.804.10
Cash at beginning of period 4.649.6810.0530.59
Stock-based compensation 3.814.882.141.60
Net cash flow / Change in cash 5.04-2.5820.59-18.14
Effect of forex changes on cash ----
Financing Cash Flow 89.309.53-0.7920.15
Dividend payments ----
Accounts receivables 1.97-1.83-3.08-1.80
Cash at end of period 9.687.0930.6412.45
Net cash provided by operating activities -36.86-41.57-51.42-42.38
Other working capital 66.06-54.350.29-0.55
Inventory 13.68-0.57-0.76-4.35

Retained Earning Schedule

Year 2016 2017 2018 2019
Retained Earnings (Previous Year) --81-74-127
Net Income -1127-54-40
Stock Dividends 32---
Dividend Paid ----
Retained Earnings -81-74-127-168

PPE Schedule

Year 2016 2017 2018 2019
Gross PPE -665
Annual Depreciation 3-1-2-1
Capital Expenditure 3110
Net PPE 6654

Intangible and Goodwill Schedule

Year 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) -1565
New Purchases -45-100-17-
Intangible and Goodwill 15654

Aptevo Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Aptevo Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.